About this trial
Trigeminal neuralgia (TN), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. Carbamazepine (CBZ) is the first-line medication for TN, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. Acupuncture, particularly electroacupuncture(EA), has demonstrated efficacy in TN treatment, although its therapeutic outcomes are influenced by various factors. Consequently, this study aims to evaluate the clinical efficacy of EA for TN and its potential as an alternative to CBZ treatment.
Eligibility criteria
Qualifiers
recurrent unilateral facial pain occurring in the distribution of one or more divisions of the trigeminal nerve, without radiation outside the trigeminal territory, and meeting criteria (2) and (3);
electric shock-like, stabbing, or sharp quality;
pain triggered by innocuous stimuli within the affected trigeminal distribution;
exclusion of other facial pain disorders classified in ICHD-3.
Disqualifiers
comorbid epilepsy, head injury, or other relevant neurological disorders;
significant impairment of cardiac, hepatic, or renal function;
cognitive dysfunction, aphasia, psychiatric conditions, or inability to cooperate with treatment;
poorly controlled hypertension or hyperglycemia;
Trial design
Treatments tested in this trial
- Carbarmazepine
- Sham Electroacupuncture
- Carbarmazepine Placebo
- Electroacupuncture
Treatment groups
Locations
Sponsors and collaborators
Yuanyuan Wu
Lead sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Sponsor institution
Pingyang County Traditional Chinese Medicine Hospital
Collaborator
Jiaxing Traditional Chinese Medicine Hospital
Collaborator